Patents Assigned to Genentech
  • Method of culturing eukaryotic cells
    Patent number: 10190084
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: January 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Dinesh Baskar, Jenny Hsiung, Woon-Lam Susan Leung, Inn H. Yuk
  • Compositions and methods for stabilizing protein-containing formulations
    Patent number: 10188735
    Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: January 29, 2019
    Assignee: GENENTECH, INC.
    Inventors: Osigwe Esue, Vikas K. Sharma
  • Therapeutic compounds, compositions and methods of use thereof
    Patent number: 10189836
    Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Rongbao Hua, Terry Kellar, Wei Li, Paul Gibbons, Mark Edward Zak
  • Methods and Compositions for Targeting Polyubiquitin
    Publication number: 20190023774
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: June 28, 2018
    Publication date: January 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • OVERLOAD AND ELUTE CHROMATOGRAPHY
    Publication number: 20190023768
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product.
    Type: Application
    Filed: April 18, 2018
    Publication date: January 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Deepa NADARAJAH, Amit MEHTA
  • METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS
    Publication number: 20190024178
    Abstract: Methods of diagnosing and treating disorders related to excess eosinophil numbers or activity, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Application
    Filed: October 9, 2018
    Publication date: January 24, 2019
    Applicant: Genentech, Inc.
    Inventors: ALEXANDER R. ABBAS, JOSEPH R. ARRON, DAVID F. CHOY, GUIQUAN JIA, NICHOLAS J.I. LEWIN-KOH, KATRINA B. MORSHEAD
  • ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20190023770
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: January 18, 2018
    Publication date: January 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Y. Chiang, Henry Chiu, Zhaoyu Jin, Zhonghua Lin, Patrick Lupardus, Gerald Nakamura, Hyunjoo Park, Lee Swem
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20190023800
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA
  • Therapeutic compounds and uses thereof
    Patent number: 10183009
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 22, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • Methods for viral inactivation and other adventitious agents
    Patent number: 10184106
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: January 22, 2019
    Assignee: Genentech, Inc.
    Inventors: Masaru Ken Shiratori, Robert David Kiss, Hardayal Prashad, Raquel Iverson, Justin Bourret, Michael Kim, Salim Charaniya
  • HIGH DOSE TREATMENTS FOR ALZHEIMER'S DISEASE
    Publication number: 20190016791
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 17, 2019
    Applicant: GENENTECH, INC.
    Inventors: Jillian Smith, Janice Smith, Geoff Kerchner
  • ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
    Publication number: 20190016807
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2018
    Publication date: January 17, 2019
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Compositions for preventing norleucine misincorporation into proteins
    Patent number: 10179925
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • Substituted benzamides and methods of use thereof
    Patent number: 10179767
    Abstract: The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 15, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Abid Hasan, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Shaoyi Sun, Andrew D. White, Wei Gong, Alla Yurevna Zenova, Jiuxiang Zhu
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 10179820
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Substituted sulfonamide compounds
    Patent number: 10179782
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Elisia Villemure, Vishal Verma, Daniel Shore, Matthew Volgraf, Baihua Hu, Aijun Lu
  • Anti-factor D antibodies
    Patent number: 10179821
    Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 15, 2019
    Assignee: GENENTECH, INC.
    Inventors: Robert F Kelley, Menno van Lookeren Campagne, Justin M Scheer, Philip E Hass, Devin Tesar
  • ANTI-LRP5 ANTIBODIES AND METHODS OF USE
    Publication number: 20190010228
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 10, 2019
    Applicant: Genentech, Inc.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • Anti-CD3 antibodies and methods of use
    Patent number: 10174124
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
    Patent number: RE47194
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet